RET inhibitors are an exciting development for non-small cell lung cancer (NSCLC) and thyroid cancers.
- Discover how RET inhibitors work and review summaries of their efficacy and safety
- Our leading experts Dr Alexander Drilon and Dr Lori Wirth highlight the importance of testing for RET gene alterations
- Hear from Professor Fernando Lopez-Rios, an expert pathologist, on improving and interpreting molecular test outcomes
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.